SAN FRANCISCO — Patients with wet age-related macular degeneration in the OPTIC trial treated with one in-office injection of ADVM-022, a gene therapy specifically designed for long-term intraocular VEGF suppression, maintained best corrected visual acuity and experienced improved central subfield thickness from baseline through 24 weeks’ follow-up, according to a speaker here.
“In the 8 months prior to OPTIC, the six patients in the first cohort received 37 injections of aflibercept. With a median of 8 months’ follow-up after intravitreal gene therapy, no rescue
Uncategorized